Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Optivia Biotechnology (United States) | Researchclopedia

Back to institutions

Optivia Biotechnology (United States)

Santa Clara, Californiacompany

21

Works

3,515

Citations

42

h-index

Top Research Topics

Drug Transport and Resistance Mechanisms Cancer Immunotherapy and Biomarkers Telomeres, Telomerase, and Senescence

Top Researchers

Lei Zhang First Affiliated Hospital of Henan University of Traditional Chinese Medicine

2,375 works38,699 citationsh-index: 87

Recent Research

102P Sustained response and long-term therapeutic benefits beyond treatment cessation in NSCLC relapsed-patients treated with ateganosine and ICI in the THIO-101 trial

T. Jankowski,Mariola Kowal-Rosinska,et al.

20260 citations

Amino Acid Enzymes and Metabolism

Computational Drug Discovery Methods

Glaucoma and retinal disorders

Pharmacogenetics and Drug Metabolism

HIV/AIDS drug development and treatment

Pharmacological Effects and Toxicity Studies

Physics of Superconductivity and Magnetism

HIV Research and Treatment

DNA Repair Mechanisms

Yan Zhang Qingdao University

349 works14,559 citationsh-index: 62

Ali Punjani Optivia Biotechnology (United States)

34 works14,497 citationsh-index: 17

Ailan Guo Cell Signaling Technology (United States)

75 works13,868 citationsh-index: 45

Shibing Deng The University of Melbourne

159 works10,591 citationsh-index: 33

JoAnn Coleman Sinai Hospital

75 works10,568 citationsh-index: 32

2084eTiP A phase III study of ateganosine (THIO; 6-thio-2'-deoxyguanosine) sequenced with immune checkpoint inhibitor (ICI) versus standard of care chemotherapy in ICI-resistant advanced NSCLC: THIO-104 trial in progress

Veronika Müller,Tomasz Jankowski,et al.

20250 citations

2083eTiP A phase II study of ateganosine (THIO; 6-thio-2'-deoxyguanosine) in combination with immune checkpoint inhibitor (ICI) in patients with advanced non-small cell lung cancer (NSCLC) resistant to prior ICI and chemotherapy: THIO-101 trial in progress

Veronika Müller,Tomasz Jankowski,et al.

20250 citations

49P: Phase II study of telomere-targeting agent THIO sequenced by cemiplimab in immune checkpoint inhibitor-resistant advanced NSCLC: Interleukin-6 as a potential predictive biomarker

Tomasz Jankowski,Tibor Csőszi,et al.

20251 citations

New Developments in Single Particle Cryo-EM Data Processing in CryoSPARC

Ali Punjani,CryoSPARC Team

20250 citations

Discovery of Competitive and Noncompetitive Ligands of the Organic Cation Transporter 1 (OCT1; SLC22A1)

Eugene C. Chen,Natalia Khuri,et al.

201764 citations